NasdaqGS:CCCCBiotechs
Has C4 Therapeutics’ (CCCC) Biogen Partnership Become a Defining Test of Its Collaborative Model?
Biogen recently announced that the U.S. FDA accepted its investigational new drug application for BIIB142, an IRAK4 degrader developed in collaboration with C4 Therapeutics, for the treatment of autoimmune diseases.
This regulatory milestone highlights C4 Therapeutics’ expertise in targeted protein degradation and the momentum in its partnerships, which are advancing clinical-stage candidates.
We'll explore how Biogen's progress with BIIB142 influences C4 Therapeutics' investment narrative...